Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRO NASDAQ:HEES NYSE:OKLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$52.08-4.1%$50.63$21.34▼$58.40$4.15B-0.151.06 million shs881,281 shsHEESH&E Equipment Services$94.64$94.46$40.93▼$101.28$3.47B1.87612,158 shsN/AOKLOOklo$68.97+2.7%$53.01$5.35▼$73.55$9.62B0.5715.04 million shs15.21 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics0.00%+0.99%-5.14%+38.40%+92.32%HEESH&E Equipment Services0.00%0.00%0.00%+4.31%+78.47%OKLOOklo0.00%+23.03%+10.82%+213.67%+677.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKROAkero Therapeutics3.7714 of 5 stars3.51.00.04.73.30.80.0HEESH&E Equipment Services2.8591 of 5 stars1.30.02.53.50.62.53.1OKLOOklo1.8977 of 5 stars2.32.00.00.02.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$82.5058.41% UpsideHEESH&E Equipment Services 2.50Moderate Buy$71.33-24.63% DownsideOKLOOklo 2.64Moderate Buy$60.25-12.64% DownsideCurrent Analyst Ratings BreakdownLatest AKRO, HEES, and OKLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025OKLOOkloCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight$73.007/15/2025OKLOOkloCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOverweight$73.007/11/2025OKLOOkloDaiwa Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$58.007/11/2025OKLOOkloDaiwa AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold6/23/2025OKLOOkloCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$59.006/12/2025OKLOOkloWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$55.00 ➝ $75.006/9/2025OKLOOkloSeaport Res PtnSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/28/2025OKLOOkloWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform5/27/2025AKROAkero TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$63.00 ➝ $64.005/27/2025OKLOOkloCLSASubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$50.00 ➝ $74.005/23/2025OKLOOkloWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$45.00 ➝ $55.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/AHEESH&E Equipment Services$1.46B2.37$14.76 per share6.41$14.66 per share6.46OKLOOkloN/AN/AN/AN/A$2.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$252.06M-$1.95N/AN/AN/AN/A-15.19%-13.97%8/8/2025 (Estimated)HEESH&E Equipment Services$169.29M$2.4924.0224.58N/A9.47%25.46%5.16%7/29/2025 (Estimated)OKLOOklo-$73.62M-$5.41N/AN/AN/AN/A-22.57%-20.19%8/12/2025 (Estimated)Latest AKRO, HEES, and OKLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025OKLOOklo-$0.12N/AN/AN/AN/AN/A8/8/2025Q2 2025AKROAkero Therapeutics-$0.95N/AN/AN/AN/AN/A7/29/2025Q2 2025HEESH&E Equipment Services$0.55N/AN/AN/A$359.60 millionN/A5/13/2025Q1 2025OKLOOklo-$0.11-$0.07+$0.04-$0.07N/AN/A5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/A4/29/2025Q1 2025HEESH&E Equipment Services$0.66$0.03-$0.63-$0.17$362.60 million$319.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/AHEESH&E Equipment Services$1.101.16%N/A44.18%N/AOKLOOkloN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0316.8016.80HEESH&E Equipment Services2.090.640.59OKLOOkloN/A36.2336.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/AHEESH&E Equipment Services84.08%OKLOOklo85.03%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.07%HEESH&E Equipment Services12.50%OKLOOklo18.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.72 million74.08 millionOptionableHEESH&E Equipment Services2,38036.67 million32.03 millionOptionableOKLOOklo78139.53 million113.16 millionOptionableAKRO, HEES, and OKLO HeadlinesRecent News About These CompaniesBrokers Issue Forecasts for Oklo FY2025 EarningsJuly 19 at 3:35 AM | americanbankingnews.comOklo (NYSE:OKLO) Shares Down 2.2% - Should You Sell?July 18 at 1:42 PM | marketbeat.comOklo (NYSE:OKLO) Trading Up 1.2% - Here's WhyJuly 17 at 6:37 PM | marketbeat.comBest Nuclear Stocks To Follow Now - July 17thJuly 17 at 3:03 PM | marketbeat.comWhy Oklo Stock Popped on ThursdayJuly 17 at 3:02 PM | fool.comOklo stock rises after passing NRC pre-application assessmentJuly 17 at 11:09 AM | investing.comOklo selects constructor for first Aurora powerhouseJuly 17 at 11:09 AM | world-nuclear-news.orgWOklo on the rise after completing NRC pre-application assessment for Aurora powerhouseJuly 17 at 11:09 AM | msn.comOklo Stock Gains After Clearing Key Regulatory Hurdle for Aurora ProjectJuly 17 at 11:09 AM | msn.comOklo Advances Licensing with Completion of NRC Readiness AssessmentJuly 17 at 8:37 AM | businesswire.comBrokers Set Expectations for Oklo FY2025 EarningsJuly 17 at 6:31 AM | marketbeat.comOklo (NYSE:OKLO) Upgraded by Cantor Fitzgerald to Overweight RatingJuly 17 at 2:15 AM | americanbankingnews.comFirm selected to build commercial energy facility at INLJuly 16, 2025 | idahobusinessreview.comITop Nuclear Stocks To Follow Today - July 16thJuly 16, 2025 | marketbeat.comOklo (NYSE:OKLO) Trading 4.1% Higher - Should You Buy?July 16, 2025 | marketbeat.comOklo (NYSE:OKLO) Stock Rating Upgraded by Cantor FitzgeraldJuly 16, 2025 | marketbeat.comSBI Securities Co. Ltd. Acquires 13,108 Shares of Oklo Inc. (NYSE:OKLO)July 16, 2025 | marketbeat.com3 Nuclear Stocks Powering the AI RevolutionJuly 16, 2025 | fool.comCantor Fitzgerald Initiates Coverage of Oklo (OKLO) with Overweight RecommendationJuly 16, 2025 | msn.comOklo picks Kiewit to lead construction of Idaho nuclear powerhouseJuly 16, 2025 | djc.comDInvestors Buy Large Volume of Oklo Call Options (NYSE:OKLO)July 16, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKRO, HEES, and OKLO Company DescriptionsAkero Therapeutics NASDAQ:AKRO$52.08 -2.25 (-4.14%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$52.74 +0.66 (+1.27%) As of 07/18/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.H&E Equipment Services NASDAQ:HEESH&E Equipment Services, Inc. engages in the provision of equipment services, which focus on heavy construction and industrial equipment. It operates through the following segments: Equipment Rentals, Sales of Rental Equipment, Sales of New Equipment, and Parts, Service and Other Revenues. The Equipment Rentals segment focuses on renting construction and industrial equipment. The Sales of Rental Equipment segment is generated primarily from sales from the rental fleet. The Sales of New Equipment segment sells equipment through a professional sales force. The Parts, Service and Other Revenues segment provides parts to the own rental fleet and sells parts for the equipment. The company was founded by Tom Engquist and Frank Head in 1961 and is headquartered in Baton Rouge, LA.Oklo NYSE:OKLO$68.97 +1.80 (+2.68%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$68.45 -0.52 (-0.75%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oklo Inc. designs and develops fission power plants to provide reliable and commercial-scale energy to customers in the United States. It also provides used nuclear fuel recycling services. The company was founded in 2013 and is based in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.